Remove Dosage Remove Immunization Remove Presentation
article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Patients often present with peripheral blood, bone marrow, and splenic involvement. 5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. There is currently no universal standard of care for MCL.

FDA
article thumbnail

Self-Care Measures for Preventing and Managing Dysmenorrhea

Pharmacy Times

SHOW MORE When no contraindications are present, most cases can be managed well with nonsteroidal anti-inflammatory drugs. 7 Clinical Presentation Dysmenorrhea presents with varying degrees of severity, and pain may occur with menses or 1 to 3 days before menses.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Pharmacy Times

Despite its proven efficacy, the conventional oral administration of lenalidomide presents challenges due to its short half-life and the high systemic exposure required to sustain therapeutic drug levels, which can lead to significant toxicities, particularly grade 3 or 4 hematologic adverse events (AEs).

article thumbnail

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacy Times

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Participants can present their work, exchange ideas, and connect with leaders in the field during these networking opportunities. AON Pharmacy's interventions saved $1.9

article thumbnail

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacy Times

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Limitations include the retrospective nature, small sample size, and lack of adjustment for multiple comparisons.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling. Presented at: Hematology/Oncology Pharmacy Association 2025 Annual Conference; April 9-12, 2025; Portland, OR. REFERENCE Soefje SA.

FDA
article thumbnail

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Pharmacy Times

Patients with inflammatory conditions achieved similar clinical outcomes after switching from the reference adalimumab (Humira; AbbVie) to a biosimilar, according to real-world data presented at the 2025 American Society of Health-System Pharmacists Pharmacy Futures Meeting. 1 REFERENCES 1. Mountain J, DaCosta SS, Zuern A. (38-M) June 7–11.